HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
Company Advances HCB101 Clinical Development, Taiwan Innovation Board Listing Process, and Global Partnering Efforts
[Taipei, Shanghai, San Francisco | May 21, 2026] – HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
Since its TPEx Emerging Stock Board registration on June 20, 2025, HanchorBio has continued to advance its capital market strategy. The Company completed a NT$680 million cash capital increase in September 2025 and submitted its application for listing on the Taiwan Innovation Board in late November 2025. The Company expects to complete the listing process by the end of May 2026, subject to applicable regulatory procedures.
During the meeting, Chairman and CEO Dr. Scott Liu thanked the Board of Directors and shareholders for their continued support. He noted that HanchorBio’s clinical and development programs are progressing steadily, and that the Company will continue to allocate resources toward assets with strong clinical differentiation and global partnering potential.
Supported by the first upfront payment from the licensing of its lead asset HCB101, HanchorBio reported 2025 revenue of NT$312 million. The Company also significantly reduced its net loss, with loss per share improving to NT$2.26, reflecting a more stable financial position.
Dr. Liu stated that 2026 marks an important transition year for HanchorBio as the Company moves from generating clinical proof-of-concept toward broader value realization across business development and capital markets. HanchorBio will prioritize core clinical assets, including HCB101, HCB301, HCB303, and HCB206, and continue to execute the “3-3-2-2+1” value matrix strategy to support clinical development, regulatory preparation, and partnering discussions.
Under this strategy, HanchorBio aims to generate Phase 2a proof-of-concept data for HCB101 across three indications in 2026, advance three programs through IND-enabling activities, support two IND applications with at least one targeting international markets, complete Phase 2a enrollment for HCB101 in second-line gastric cancer, and continue pursuing international licensing opportunities as the “+1” component of the strategy.
HanchorBio also continues to expand clinical proof-of-concept opportunities across additional indications while strengthening the differentiated position of its proprietary FBDB™ platform. The Company is aligning its business development activities closely with upcoming clinical milestones and continues to evaluate international partnering opportunities that may support future clinical development and long-term value creation.
Looking ahead, HanchorBio will remain focused on advancing breakthrough therapies in oncology and autoimmune diseases, increasing the partnering potential of its core assets, and optimizing resource allocation to support long-term shareholder value.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.
首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點
推進HCB101臨床開發、創新板上市進程及國際合作布局
專注創新藥物開發的漢康-KY（股票代碼：7827）今（21）日召開股東常會，會中順利通過各項議案，並承認去年營業報告書、財務報表與虧損撥補案。漢康-KY於去年6月20日登櫃後，資本市場進程推進迅速，不僅於同年9月順利完成新台幣6.8億元現金增資，更於11月底遞交創新板上市申請，預計今年5月底前正式掛牌上市，展現健全且高效的資本布局。
今日股東會由董事長劉世高主持，首先感謝董事及全體股東在公司登錄興櫃首年的鼎力支持，並表示旗下新藥產品正穩步推進研發與臨床試驗，公司將持續投入資源，加速產品開發與價值累積，為下一階段成長奠定基礎。公司受惠於核心新藥HCB101首筆授權金的挹注，去年營收達新台幣3.12億元，虧損大幅收斂，每股虧損（EPS）顯著改善至2.26元，財務結構趨於穩健。
劉世高強調，今年是漢康-KY從「臨床概念驗證」邁向「商業與資本市場價值兌現」的關鍵轉折年。公司將集中資源聚焦發展具備高授權變現潛力的臨床資產，如HCB101、HCB301、HCB303與HCB206等核心產品，並積極採取「3-3-2-2+1」價值矩陣策略，以支持臨床開發、法規準備及國際合作布局。
在此策略藍圖下，廣譜抗癌新藥HCB101將爭取今年內達成3項適應症的臨床2a期概念驗證（POC）數據，以多元資產價值來分散單一藥物研發風險；同時將推進3個項目完成臨床前試驗準備（IND-enabling）與正式申報，確保具備國際標準的完整授權用數據。在臨床申請方面，則規劃推動2個研發項目完成臨床試驗（IND）申請，其中至少一項以國際市場為導向，確保法規策略與商業開發同步。此外，核心新藥HCB101針對二線胃癌的臨床試驗也預計於年內完成2a期收案；同時，持續推進國際授權與合作機會，作為「+1」策略的重要組成。
劉世高進一步表示，公司將持續拓展更多適應症以取得臨床POC機會，同時強化自主FBDB™平台之差異化優勢。
劉世高也指出，公司正結合臨床里程碑與商務發展節奏，持續評估國際合作機會，以支持未來臨床開發與長期價值成長。
展望今年，劉世高表示，公司將持續專注於腫瘤免疫及自體免疫疾病領域之創新療法開發，利用自主開發的FBDB™技術平台加速新藥研發。未來1至2年內，營運將高度聚焦於提升核心資產之國際合作潛力，並透過資源最適化配置，支持長期股東價值之提升。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。